MA022-2037

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameMA022-2037
Drug Alias Nameanti-CD3/anti-KRAS G12V/HLA-A*11:01 bispecific T-cell engager (Myrio Therapeutics)MA022-2037MA-022-2037
ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionAnti-KRAS G12VCD3 T-cell engagers
TargetsKRAS G12VT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMyrio Therapeutics Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMyrio Therapeutics Pty Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A